Adakveo® (crizanlizumab-tmca)

Adakveo (crizanlizumab‑tmca) is covered to reduce vaso‑occlusive crises in sickle cell disease patients aged ≥16 years (patients <16 excluded), limited to the FDA indication, approved up to 12 months with dosing per FDA (5 mg/kg IV at Weeks 0 and 2, then every 4 weeks). Authorization requires ≥1 sickle‑cell–related crisis in the prior 12 months, either current hydroxyurea use or documented hydroxyurea inadequate efficacy/intolerance or ineligibility, prescription by or consultation with a sickle cell specialist, and reauthorization requires documented clinical benefit.

"Adakveo is indicated to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease."

Sign up to see full coverage criteria, indications, and limitations.